BioLife Solutions, Inc.'s (NASDAQ:BLFS) Shift From Loss To Profit

BioLife Solutions, Inc. (NASDAQ:BLFS) is possibly approaching a major achievement in its business, so we would like to shine some light on the company. BioLife Solutions, Inc. develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The US$1.2b market-cap company posted a loss in its most recent financial year of US$66m and a latest trailing-twelve-month loss of US$64m shrinking the gap between loss and breakeven. Many investors are wondering about the rate at which BioLife Solutions will turn a profit, with the big question being “when will the company breakeven?” In this article, we will touch on the expectations for the company's growth and when analysts expect it to become profitable.

Check out our latest analysis for BioLife Solutions

Consensus from 10 of the American Life Sciences analysts is that BioLife Solutions is on the verge of breakeven. They anticipate the company to incur a final loss in 2025, before generating positive profits of US$6.4m in 2026. Therefore, the company is expected to breakeven roughly 2 years from now. How fast will the company have to grow each year in order to reach the breakeven point by 2026? Working backwards from analyst estimates, it turns out that they expect the company to grow 71% year-on-year, on average, which is rather optimistic! Should the business grow at a slower rate, it will become profitable at a later date than expected.

Underlying developments driving BioLife Solutions' growth isn’t the focus of this broad overview, however, bear in mind that by and large life science companies, depending on the stage of product development, have irregular periods of cash flow. This means, large upcoming growth rates are not abnormal as the company is beginning to reap the benefits of earlier investments.

Before we wrap up, there’s one aspect worth mentioning. The company has managed its capital prudently, with debt making up 6.6% of equity. This means that it has predominantly funded its operations from equity capital, and its low debt obligation reduces the risk around investing in the loss-making company.

Next Steps:

This article is not intended to be a comprehensive analysis on BioLife Solutions, so if you are interested in understanding the company at a deeper level, take a look at BioLife Solutions' company page on Simply Wall St. We've also put together a list of relevant factors you should look at:

1. Valuation: What is BioLife Solutions worth today? Has the future growth potential already been factored into the price? The intrinsic value infographic in our free research report helps visualize whether BioLife Solutions is currently mispriced by the market.
2. Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on BioLife Solutions’s board and the CEO’s background.
3. Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.